ANI Pharmaceuticals announced the launch of Promethazine Hydrochloride and Dextromethorphan Hydrobromide Oral Solution, 6.25 mg/15 mg per 5 mL. U.S. annual sales for Promethazine Hydrochloride and Dextromethorphan Hydrobromide Oral Solution total approximately $42.6M, based on July 2024 moving annual total IQVIA data.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANIP:
- Salesforce downgraded, Charter upgraded: Wall Street’s top analyst calls
- ANI Pharmaceuticals, Alimera Sciences merger to close on September 16
- ANI Pharmaceuticals and Alimera Sciences Announce Closing Date of Merger
- ANI Pharmaceuticals downgraded to Hold from Buy at Truist
- ANI says working in ‘good faith’ to close Alimera acquisition